Jefferies upgraded Fisher & Paykel Healthcare to Buy from Hold with a price target of NZ$40.90, up from NZ$39.40. Fisher & Paykel successfully converted clinical change into product sales through FY25, even with a moderate flu season, says the firm, which believes limited tariff impacts and the company’s practice of continuous process improvement should lead to increased operating leverage.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FSPKF:
- Fisher & Paykel Healthcare downgraded to Underperform at RBC Capital
- Fisher & Paykel Healthcare Surpasses $2 Billion Revenue Milestone
- Fisher & Paykel Healthcare Announces Dividend Distribution
- Fisher & Paykel Healthcare Achieves Record Revenue in 2025
- Fisher & Paykel Healthcare Announces Investor Event in Melbourne